Traussnigg, Stefan
Halilbasic, Emina
Hofer, Harald
Munda, Petra
Stojakovic, Tatjana
Fauler, Günter
Kashofer, Karl
Krssak, Martin
Wolzt, Michael
Trauner, Michael
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 22 May 2020
Accepted: 11 August 2020
First Online: 15 September 2020
Compliance with ethical guidelines
:
: S. Traussnigg, E. Halilbasic, H. Hofer, P. Munda, T. Stojakovic, G. Fauler, K. Kashofer, M. Krssak, and M. Wolzt declare that they have no competing interests. M. Trauner served as a consultant for Albireo, BiomX, Falk, Genfit, Gilead, Intercept, Janssen, MSD, Novartis, Phenex and Regulus and is a member of the speakers’ bureau of Falk, Gilead, Intercept MSD and Roche. He further received travel grants from AbbVie, Falk, Roche and Gilead and unrestricted research grants from Albireo, Cymabay, Falk, Intercept, MSD and Takeda. He is also co-inventor of a patent on the medical use of nor-UDCA filed by the Medical University of Graz.
: All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all patients for being included in the study.